Canada’s Drug Agency has released new guidance around aging in place. This guidance is intended to help health systems address Canada’s demographic transition toward an increasingly diverse aging population with an increased need for care and support during the later stages of life.
As health…
Today’s the day: we are officially Canada’s Drug Agency.
We are expanding on our existing mandate and functions — which span drugs, medical devices, and clinical interventions — and including developing new programs focused on appropriate use, data and analytics, and system coordination and…
Canada’s Drug Agency has published a national inventory of rare disease registries (RDRs) that includes both registries in Canada and international registries with participants who live in Canada.
The inventory is designed to serve as a centralized, thorough repository of registries that collect…
Canada’s Drug Agency is pleased to announce the recipients of our 2024 Recognition Awards. These awards honour individuals who are pushing the science of health technology assessment (HTA) forward, mentoring the next generation of leaders, and helping to grow Canada’s reputation for excellence in…
A new Environmental Scan from Canada’s Drug Agency examines Canadian data related to alternate level of care (ALC) and the effectiveness of strategies health systems use to reduce ALC times.
ALC is a designation that refers to people who occupy a hospital bed, but who don’t require the intensity of…
Canada’s Drug Agency has published a summary report from its time-limited Industry Task Force. The report outlines key actions for the organization, and the broader health care community, that can enable the use of industry-sponsored real-world evidence (RWE) to help improve our understanding of…
Patients in Canada with advanced-stage lymphoma are 1 step closer to accessing the first drug to receive a time-limited reimbursement recommendation from Canada’s Drug Agency.
Epcoritamab (brand name Epkinly) is a subcutaneous bispecific antibody used to treat adults with relapsed or refractory…
Last week, the Government of Canada released the final report from the Canadian Drug Agency Transition Office’s (CDATO) Appropriate Use Advisory Committee on the appropriate use of medications.
These recommendations and the strong foundation established by the CDATO will support Canada’s Drug…
Canada’s Drug Agency is taking a new step to improve the timeliness of patient access to new drugs. The action supports our ambitious Target Zero campaign — an initiative that aims to achieve zero days between Health Canada’s regulatory approval of a drug and our reimbursement recommendation to…
A new evidence report from Canada’s Drug Agency identifies key factors that influence the ability of older adults in Canada to age in place and the systematic factors to consider when implementing initiatives that can allow people to age at home or in the community.
Aging in place is the ability of…
Current consultation status: Open Consultation period: July 11, 2024, to September 11, 2024
Canada’s Drug Agency is developing pan-Canadian guidance to support decision-making related to newborn screening. This work is being led by our Newborn Screening Advisory Panel and supports the…
Canada’s Drug Agency is advancing our commitment to building meaningful relationships with patient communities by establishing a new Patient Member role on our Board of Directors. Through our open call for nominations, we are seeking a dedicated and experienced individual who will bring new…